MEDA

Acquisition of Acton Pharmaceuticals completed

Mon, Oct 21, 2013 08:00 CET

On August 30th, 2013, Meda announced the acquisition of Acton Pharmaceuticals, Inc. and its proprietary product Aerospan. The acquisition has now been completed. The purchase price for Acton amounted to 135 MUSD, on a cash and debt free basis. In addition, there is a milestone payment of 10 million USD and royalty based milestones. About Aerospan Aerospan (flunisolide HFA, 80 mcg) is approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of asthma in adult and pediatric patients 6 years of age and older. Aerospan is the first and only product registered in the US

MEDA acquires a US respiratory company

Fri, Aug 30, 2013 12:00 CET

Meda has signed an agreement to acquire the US development company Acton Pharmaceuticals, Inc. (“Acton”) including the proprietary product Aerospan. Aerospan is an inhaler for the treatment of asthma that contains the active substance Flunisolide. The product is approved by the FDA and has shown in clinical studies to have a high deposition of active drug in the airways as a result of a built-in inhalation chamber (called a “spacer”). In a randomized double-blind placebo-controlled study, published in the Annals of Allergy, Asthma & Immunology, Aerospan show no significant negative

Share

About Us

Acquisition of Acton Pharmaceuticals completed

MEDA acquires a US respiratory company